As the Covid-19 pandemic has begun to ease, with vaccines being manufactured and distributed, more clinical trials are continuing to resume. Data captured from GlobalData’s Pharma Intelligence Centre on 28 June shows that more than 1,000 trials have resumed, with resumed trials showing a widespread distribution over therapy areas.
Out of the resumed trials, 30.5% are currently in the oncology therapy area, followed by the central nervous system at 19.6% and infectious diseases at 8.3%. The figure below shows the top ten therapy areas for resumed trials. Since the beginning of the year, oncology has seen a 10.3% increase. The central nervous system saw the biggest increase in the number of resumed clinical trials since early in the year at 29.6%, while dermatology had the smallest increase at 5.6%.
These numbers suggest a positive outlook for resumed clinical trials, although this could be slowed by new variant strains such as Delta and warnings of new waves of the original Covid-19 strain.